CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.
暂无分享,去创建一个
S. Khoo | A. Owen | D. Back | A. Schipani | M. Siccardi | A. Olagunju | D. Egan
[1] V. Haufroid,et al. Impact of CYP3A4*22 Allele on Tacrolimus Pharmacokinetics in Early Period After Renal Transplantation: Toward Updated Genotype-Based Dosage Guidelines , 2013, Therapeutic drug monitoring.
[2] G. Koren,et al. CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. , 2013, Pharmacogenomics.
[3] D. Hesselink,et al. The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. , 2013, British journal of clinical pharmacology.
[4] U. Zanger,et al. Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the “Missing Heritability” Problem , 2013, Front. Genet..
[5] V. Haufroid,et al. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. , 2013, Pharmacogenomics.
[6] Laurent Gil,et al. Ensembl 2013 , 2012, Nucleic Acids Res..
[7] M. Youle,et al. Estimation of the Effect of Slco1B1 Polymorphisms on Lopinavir Plasma Concentration in HIV-Infected Adults , 2012, Antiviral therapy.
[8] Jie Lu,et al. CPY3A4-Mediated Lopinavir Bioactivation and Its Inhibition by Ritonavir , 2012, Drug Metabolism and Disposition.
[9] V. Haufroid,et al. Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition , 2011, Pharmacogenetics and genomics.
[10] A. Hofman,et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study , 2011, Pharmacogenetics and genomics.
[11] V. Haufroid,et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. , 2011, Clinical chemistry.
[12] V. Haufroid,et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. , 2011, Pharmacogenomics.
[13] W. Sadee,et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs , 2011, The Pharmacogenomics Journal.
[14] J. Absalon,et al. Gastrointestinal tolerability and quality of life in antiretroviral-naïve HIV-1-infected patients: data from the CASTLE study , 2010, AIDS care.
[15] J. Absalon,et al. Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study , 2010, Journal of acquired immune deficiency syndromes.
[16] S. Khoo,et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms , 2010, Pharmacogenetics and genomics.
[17] Matthias Cavassini,et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir , 2010, Pharmacogenetics and genomics.
[18] V. Haufroid,et al. Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. , 2009, Pharmacogenomics.
[19] G. Morse,et al. Pharmacogenomics of CYP3A: considerations for HIV treatment. , 2009, Pharmacogenomics.
[20] S. Khoo,et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] Danielson Pb,et al. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. , 2002 .
[22] A. Paterson,et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. , 2000, Pharmacogenetics.
[23] P. Vouros,et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[24] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[25] B. Dvorchik,et al. Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[26] V. Haufroid,et al. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. , 2013, Pharmacogenomics.
[27] G. Suarez-Kurtz,et al. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. , 2010, British journal of clinical pharmacology.
[28] J. Schapiro,et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. , 2006 .
[29] P. Danielson,et al. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. , 2002, Current drug metabolism.